These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 34131191)

  • 1. Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
    Gil-Bernal R; González-Caballero JL; Espinosa-Rosso R; Gómez-Gómez C
    Sci Rep; 2021 Jun; 11(1):12533. PubMed ID: 34131191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
    Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
    JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple sclerosis, a treatable disease .
    Doshi A; Chataway J
    Clin Med (Lond); 2017 Dec; 17(6):530-536. PubMed ID: 29196354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
    Reder AT; Centonze D; Naylor ML; Nagpal A; Rajbhandari R; Altincatal A; Kim M; Berdofe A; Radhakrishnan M; Jung E; Sandrock AW; Smirnakis K; Popescu C; de Moor C
    CNS Drugs; 2021 Mar; 35(3):317-330. PubMed ID: 33743151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
    Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
    J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
    Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.
    Rommer PS; Zettl UK
    Expert Opin Pharmacother; 2018 Apr; 19(5):483-498. PubMed ID: 29528247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Ingwersen J; Aktas O; Hartung HP
    Neurotherapeutics; 2016 Jan; 13(1):47-57. PubMed ID: 26701666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
    Braune S; Grimm S; van Hövell P; Freudensprung U; Pellegrini F; Hyde R; Bergmann A;
    J Neurol; 2018 Dec; 265(12):2980-2992. PubMed ID: 30327931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
    Safavi F; Nourbakhsh B; Azimi AR
    Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis.
    Dashputre AA; Kamal KM; Pawar G
    J Manag Care Spec Pharm; 2017 Jun; 23(6):666-676. PubMed ID: 28530523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL; Tyor WR
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
    Diouf I; Malpas CB; Sharmin S; Roos I; Horakova D; Kubala Havrdova E; Patti F; Shaygannejad V; Ozakbas S; Eichau S; Onofrj M; Lugaresi A; Alroughani R; Prat A; Duquette P; Terzi M; Boz C; Grand'Maison F; Sola P; Ferraro D; Grammond P; Yamout B; Altintas A; Gerlach O; Lechner-Scott J; Bergamaschi R; Karabudak R; Iuliano G; McGuigan C; Cartechini E; Hughes S; Sa MJ; Solaro C; Kappos L; Hodgkinson S; Slee M; Granella F; de Gans K; McCombe PA; Ampapa R; van der Walt A; Butzkueven H; Sánchez-Menoyo JL; Vucic S; Laureys G; Sidhom Y; Gouider R; Castillo-Trivino T; Gray O; Aguera-Morales E; Al-Asmi A; Shaw C; Al-Harbi TM; Csepany T; Sempere AP; Treviño Frenk I; Stuart EA; Kalincik T
    J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):1004-1011. PubMed ID: 37414534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
    English C; Aloi JJ
    Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
    Chen J; Taylor BV; Blizzard L; Simpson S; Palmer AJ; van der Mei IAF
    J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1200-1207. PubMed ID: 29921609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pregnancy and Multiple Sclerosis: An Update on the Disease Modifying Treatment Strategy and a Review of Pregnancy's Impact on Disease Activity.
    Varytė G; Zakarevičienė J; Ramašauskaitė D; Laužikienė D; Arlauskienė A
    Medicina (Kaunas); 2020 Jan; 56(2):. PubMed ID: 31973138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
    Pistono C; Osera C; Boiocchi C; Mallucci G; Cuccia M; Bergamaschi R; Pascale A
    Pharmacol Res; 2017 Jun; 120():279-293. PubMed ID: 28396093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.